Lisdexamfetamine: A pharmacokinetic review.
暂无分享,去创建一个
[1] C. Bulik,et al. Updates on Genome-wide Association Findings in Eating Disorders and Future Application to Precision Medicine , 2018, Current neuropharmacology.
[2] M. Liechti,et al. Pharmacokinetics and Pharmacodynamics of Lisdexamfetamine Compared with D-Amphetamine in Healthy Subjects , 2017, Front. Pharmacol..
[3] J. Najib,et al. Pharmacologic and Pharmacokinetic Aspects Lisdexamfetamine dimesylate is a water-soluble prodrug of the single isomer—d-amphetamine and l-lysine—that remains Review of Lisdexamfetamine Dimesylate in Adults With Attention-Deficit/Hyperactivity Disorder , 2017 .
[4] K. Lasseter,et al. A Single-Dose, Open-Label Study of the Pharmacokinetics, Safety, and Tolerability of Lisdexamfetamine Dimesylate in Individuals With Normal and Impaired Renal Function , 2016, Therapeutic drug monitoring.
[5] M. Corcoran,et al. Lisdexamfetamine Dimesylate Effects on the Pharmacokinetics of Cytochrome P450 Substrates in Healthy Adults in an Open-Label, Randomized, Crossover Study , 2015, Drugs in R&D.
[6] S. McElroy,et al. Efficacy and safety of lisdexamfetamine for treatment of adults with moderate to severe binge-eating disorder: a randomized clinical trial. , 2015, JAMA psychiatry.
[7] M. Corcoran,et al. Safety and Pharmacokinetics of Lisdexamfetamine Dimesylate in Adults With Clinically Stable Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Trial of Ascending Multiple Doses , 2014, Journal of clinical psychopharmacology.
[8] R. Secker,et al. Preclinical pharmacokinetics, pharmacology and toxicology of lisdexamfetamine: A novel d-amphetamine pro-drug , 2014, Neuropharmacology.
[9] M. Pennick,et al. Lisdexamfetamine prodrug activation by peptidase-mediated hydrolysis in the cytosol of red blood cells , 2014, Neuropsychiatric disease and treatment.
[10] D. Coghill,et al. P.7.f.009 Lisdexamfetamine dimesylate: hydrolysis, pharmacokinetics and duration of therapeutic action in children and adolescents with ADHD , 2014, European Neuropsychopharmacology.
[11] D. Coghill,et al. A Systematic Review of the Safety of Lisdexamfetamine Dimesylate , 2014, CNS Drugs.
[12] P. Mattos. Lisdexamfetamine dimesylate in the treatment of attention-deficit/hyperactivity disorder: pharmacokinetics, efficacy and safety in children and adolescents , 2014 .
[13] Tristan Shuman,et al. Psychostimulants and Cognition: A Continuum of Behavioral and Cognitive Activation , 2014, Pharmacological Reviews.
[14] Janet B W Williams. Diagnostic and Statistical Manual of Mental Disorders , 2013 .
[15] M. Corcoran,et al. Pharmacokinetics of Coadministered Guanfacine Extended Release and Lisdexamfetamine Dimesylate , 2013, Drugs in R&D.
[16] K. Lasseter,et al. An Open-Label Investigation of the Pharmacokinetic Profiles of Lisdexamfetamine Dimesylate and Venlafaxine Extended-Release, Administered Alone and in Combination, in Healthy Adults , 2013, Clinical Drug Investigation.
[17] M. Pennick. Metabolism of the prodrug lisdexamfetamine dimesylate in human red blood cells from normal and sickle cell disease donors* , 2013, Journal of drug assessment.
[18] K. Lasseter,et al. Double-blind, placebo-controlled, two-period, crossover trial to examine the pharmacokinetics of lisdexamfetamine dimesylate in healthy older adults , 2013, Neuropsychiatric disease and treatment.
[19] Mats Johnson,et al. Lisdexamfetamine Dimesylate , 2012, CNS Drugs.
[20] A. Childress. Guanfacine Extended Release as Adjunctive Therapy to Psychostimulants in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder , 2012, Advances in Therapy.
[21] M. Corcoran,et al. Pharmacokinetics of Lisdexamfetamine Dimesylate after Targeted Gastrointestinal Release or Oral Administration in Healthy Adults , 2012, Drug Metabolism and Disposition.
[22] F. Sallee,et al. The use of lisdexamfetamine dimesylate for the treatment of ADHD , 2012, Expert review of neurotherapeutics.
[23] Michael L. Pucci,et al. Pharmacokinetic Variability of Long-Acting Stimulants in the Treatment of Children and Adults with Attention-Deficit Hyperactivity Disorder , 2010, CNS drugs.
[24] Patrick Martin,et al. Lisdexamfetamine Dimesylate: Linear Dose‐Proportionality, Low Intersubject and Intrasubject Variability, and Safety in an Open‐Label Single‐Dose Pharmacokinetic Study in Healthy Adult Volunteers , 2010, Journal of clinical pharmacology.
[25] O. Bukstein,et al. Management of the adolescent with substance use disorders and comorbid psychopathology. , 2010, Child and adolescent psychiatric clinics of North America.
[26] M. Pennick. Absorption of lisdexamfetamine dimesylate and its enzymatic conversion to d-amphetamine , 2010, Neuropsychiatric disease and treatment.
[27] G. Mattingly. Lisdexamfetamine Dimesylate: A Prodrug Stimulant for the Treatment of ADHD in Children and Adults , 2010, CNS Spectrums.
[28] David W Goodman,et al. Lisdexamfetamine dimesylate (vyvanse), a prodrug stimulant for attention-deficit/hyperactivity disorder. , 2010, P & T : a peer-reviewed journal for formulary management.
[29] J. Stark,et al. Pharmacokinetics of lisdexamfetamine dimesylate and its active metabolite, d-amphetamine, with increasing oral doses of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: a single-dose, randomized, open-label, crossover study. , 2010, Clinical therapeutics.
[30] S. Cheetham,et al. The neuropharmacology of ADHD drugs in vivo: Insights on efficacy and safety , 2009, Neuropharmacology.
[31] P. Bhattacharya,et al. Lisdexamfetamine: a prodrug for the treatment of attention-deficit/hyperactivity disorder. , 2009, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[32] K. Lasseter,et al. Effects of Omeprazole on the Pharmacokinetic Profiles of Lisdexamfetamine Dimesylate and Extended-Release Mixed Amphetamine Salts in Adults , 2009, Postgraduate medicine.
[33] D. Jasinski,et al. Human pharmacology of intravenous lisdexamfetamine dimesylate: abuse liability in adult stimulant abusers , 2009, Journal of psychopharmacology.
[34] A. Arnsten,et al. The Emerging Neurobiology of Attention Deficit Hyperactivity Disorder: The Key Role of the Prefrontal Association Cortex. , 2009, The Journal of pediatrics.
[35] Brian J. Cowles. Lisdexamfetamine for Treatment of Attention-Deficit/Hyperactivity Disorder , 2009, The Annals of pharmacotherapy.
[36] S. Krishnan,et al. Relative Bioavailability of Lisdexamfetamine 70‐mg Capsules in Fasted and Fed Healthy Adult Volunteers and in Solution: A Single‐Dose, Crossover Pharmacokinetic Study , 2008, Journal of clinical pharmacology.
[37] R. Doyle,et al. Onset of Efficacy of Long-Acting Psychostimulants in Pediatric Attention-Deficit/Hyperactivity Disorder , 2008, Postgraduate medicine.
[38] J. Stark,et al. Multiple daily-dose pharmacokinetics of lisdexamfetamine dimesylate in healthy adult volunteers , 2008, Current medical research and opinion.
[39] J. Biederman,et al. Lisdexamfetamine Dimesylate and Mixed Amphetamine Salts Extended-Release in Children with ADHD: A Double-Blind, Placebo-Controlled, Crossover Analog Classroom Study , 2007, Biological Psychiatry.
[40] S. Krishnan,et al. An Evaluation of the Cytochrome P450 Inhibition Potential of Lisdexamfetamine in Human Liver Microsomes , 2007, Drug Metabolism and Disposition.
[41] N. Volkow,et al. Abuse of prescription drugs and the risk of addiction. , 2006, Drug and alcohol dependence.
[42] Patrick Martin,et al. Intranasal versus Oral Administration of Lisdexamfetamine Dimesylate , 2011, Clinical drug investigation.
[43] J. Najib. The efficacy and safety profile of lisdexamfetamine dimesylate, a prodrug of d-amphetamine, for the treatment of attention-deficit/hyperactivity disorder in children and adults. , 2009, Clinical therapeutics.
[44] J. Stark,et al. Metabolism, Distribution and Elimination of Lisdexamfetamine Dimesylate , 2008, Clinical drug investigation.